Robbins LLP Is Investigating the Officers and Directors of Poseida Therapeutics, Inc. (PSTX) on Behalf of Shareholders
Robbins LLP Is Investigating the Officers and Directors of Poseida Therapeutics, Inc. (PSTX) on Behalf of Shareholders
SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP is investigating whether Poseida Therapeutics, Inc. (NASDAQ: PSTX) and its officers and directors violated securities laws and engaged in unlawful business practices in connection with its initial public offering ("IPO"). Poseida is a clinical-stage biopharmaceutical company that develops therapeutics for patients with high unmet medical needs.
If you have suffered a loss due to Poseida Therapeutics, Inc.'s misconduct, click here.
Poseida conducted its IPO on July 10, 2020, issuing 14 million shares for $16.00 per share. On August 18, 2020, Poseida announced that the U.S. Food and Drug Administration had placed a clinical hold on its Phase 1 clinical trial evaluating the autologous CAR-T therapy P-PSMA-101 in patients with metastatic castration-resistant prostate cancer due to a patient's death. On this news, Poseida's stock fell 30.31%, to close at $9.06 on August 18, 2020.
Poseida Therapeutics, Inc. (PSTX) Shareholders Have Legal Options
Contact us to learn more:
Lauren Levi
(800) 350-6003
llevi@robbinsllp.com
Shareholder Information Form
Robbins LLP is a nationally recognized leader in shareholder rights law. To be notified if a class action against Poseida settles or to receive free alerts about companies engaged in wrongdoing, sign up for Stock Watch today.
Attorney Advertising. Past results do not guarantee a similar outcome.
Contacts
Lauren Levi
Robbins LLP
llevi@robbinsllp.com
(800) 350-6003
www.robbinsllp.com
